Plasma leptin and adiposity during antipsychotic treatment or schizophrenia

Daniel (Dan) Haupt, Angela Luber, Justin Maeda, Angela K. Melson, Julie A. Schweiger, John W. Newcomer

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Alterations in plasma leptin have been reported in schizophrenia patients treated with antipsychotics, suggesting the hypothesis that impairments in leptin secretion or signaling might play a role in antipsychotic-induced weight gain. Plasma leptin was measured in 72 schizophrenia patients chronically treated with olanzapine (n = 27), risperldone (n = 24) or typical antipsychotics (n = 21) and 124 healthy adult control subjects, ANCOVA was used to test effects of adiposity (body mass index kg/m2; BMI), subject group (treated patients vs untreated controls), and treatment group (specific medication groups and untreated controls) on plasma leptin concentrations. Additional analyses were performed in a subset of patients and controls individually matched for BMI to further assess group differences in plasma leptin independent of adiposity. BMI strongly predicted plasma leptin concentrations in the overall sample. In addition, a significant three-way interaction between BMI, subject group, and gender was observed. In the individually BMI-matched sample, modestly reduced plasma leptin levels (effect size 0.4 SD) were observed in treated patients in comparison to the BMI-matched healthy controls, with both groups including males and females. However, no differences in plasma leptin levels were observed in the matched sample when separately companng male patients vs untreated male controls and female patients vs untreated female controls. Plasma leptin in chronically treated patients with schizophrenia is strongly predicted by adiposity, similar to untreated healthy individuals despite adequate power to detect a difference. The results argue against a role for defective leptin secretion or sensitivity in the weight gain induced by antipsychotic medications.

Original languageEnglish (US)
Pages (from-to)184-191
Number of pages8
JournalNeuropsychopharmacology
Volume30
Issue number1
DOIs
StatePublished - Jan 2005
Externally publishedYes

Fingerprint

Adiposity
Leptin
Antipsychotic Agents
Schizophrenia
Therapeutics
olanzapine
Weight Gain
Control Groups
Body Mass Index

Keywords

  • Antipsychotics
  • Human
  • Leptin
  • Obesity
  • Schizophrenia
  • Weight gain

ASJC Scopus subject areas

  • Pharmacology

Cite this

Haupt, D. D., Luber, A., Maeda, J., Melson, A. K., Schweiger, J. A., & Newcomer, J. W. (2005). Plasma leptin and adiposity during antipsychotic treatment or schizophrenia. Neuropsychopharmacology, 30(1), 184-191. https://doi.org/10.1038/sj.npp.1300563

Plasma leptin and adiposity during antipsychotic treatment or schizophrenia. / Haupt, Daniel (Dan); Luber, Angela; Maeda, Justin; Melson, Angela K.; Schweiger, Julie A.; Newcomer, John W.

In: Neuropsychopharmacology, Vol. 30, No. 1, 01.2005, p. 184-191.

Research output: Contribution to journalArticle

Haupt, DD, Luber, A, Maeda, J, Melson, AK, Schweiger, JA & Newcomer, JW 2005, 'Plasma leptin and adiposity during antipsychotic treatment or schizophrenia', Neuropsychopharmacology, vol. 30, no. 1, pp. 184-191. https://doi.org/10.1038/sj.npp.1300563
Haupt, Daniel (Dan) ; Luber, Angela ; Maeda, Justin ; Melson, Angela K. ; Schweiger, Julie A. ; Newcomer, John W. / Plasma leptin and adiposity during antipsychotic treatment or schizophrenia. In: Neuropsychopharmacology. 2005 ; Vol. 30, No. 1. pp. 184-191.
@article{cab58e0bca184775b797cf563e4888b8,
title = "Plasma leptin and adiposity during antipsychotic treatment or schizophrenia",
abstract = "Alterations in plasma leptin have been reported in schizophrenia patients treated with antipsychotics, suggesting the hypothesis that impairments in leptin secretion or signaling might play a role in antipsychotic-induced weight gain. Plasma leptin was measured in 72 schizophrenia patients chronically treated with olanzapine (n = 27), risperldone (n = 24) or typical antipsychotics (n = 21) and 124 healthy adult control subjects, ANCOVA was used to test effects of adiposity (body mass index kg/m2; BMI), subject group (treated patients vs untreated controls), and treatment group (specific medication groups and untreated controls) on plasma leptin concentrations. Additional analyses were performed in a subset of patients and controls individually matched for BMI to further assess group differences in plasma leptin independent of adiposity. BMI strongly predicted plasma leptin concentrations in the overall sample. In addition, a significant three-way interaction between BMI, subject group, and gender was observed. In the individually BMI-matched sample, modestly reduced plasma leptin levels (effect size 0.4 SD) were observed in treated patients in comparison to the BMI-matched healthy controls, with both groups including males and females. However, no differences in plasma leptin levels were observed in the matched sample when separately companng male patients vs untreated male controls and female patients vs untreated female controls. Plasma leptin in chronically treated patients with schizophrenia is strongly predicted by adiposity, similar to untreated healthy individuals despite adequate power to detect a difference. The results argue against a role for defective leptin secretion or sensitivity in the weight gain induced by antipsychotic medications.",
keywords = "Antipsychotics, Human, Leptin, Obesity, Schizophrenia, Weight gain",
author = "Haupt, {Daniel (Dan)} and Angela Luber and Justin Maeda and Melson, {Angela K.} and Schweiger, {Julie A.} and Newcomer, {John W.}",
year = "2005",
month = "1",
doi = "10.1038/sj.npp.1300563",
language = "English (US)",
volume = "30",
pages = "184--191",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Plasma leptin and adiposity during antipsychotic treatment or schizophrenia

AU - Haupt, Daniel (Dan)

AU - Luber, Angela

AU - Maeda, Justin

AU - Melson, Angela K.

AU - Schweiger, Julie A.

AU - Newcomer, John W.

PY - 2005/1

Y1 - 2005/1

N2 - Alterations in plasma leptin have been reported in schizophrenia patients treated with antipsychotics, suggesting the hypothesis that impairments in leptin secretion or signaling might play a role in antipsychotic-induced weight gain. Plasma leptin was measured in 72 schizophrenia patients chronically treated with olanzapine (n = 27), risperldone (n = 24) or typical antipsychotics (n = 21) and 124 healthy adult control subjects, ANCOVA was used to test effects of adiposity (body mass index kg/m2; BMI), subject group (treated patients vs untreated controls), and treatment group (specific medication groups and untreated controls) on plasma leptin concentrations. Additional analyses were performed in a subset of patients and controls individually matched for BMI to further assess group differences in plasma leptin independent of adiposity. BMI strongly predicted plasma leptin concentrations in the overall sample. In addition, a significant three-way interaction between BMI, subject group, and gender was observed. In the individually BMI-matched sample, modestly reduced plasma leptin levels (effect size 0.4 SD) were observed in treated patients in comparison to the BMI-matched healthy controls, with both groups including males and females. However, no differences in plasma leptin levels were observed in the matched sample when separately companng male patients vs untreated male controls and female patients vs untreated female controls. Plasma leptin in chronically treated patients with schizophrenia is strongly predicted by adiposity, similar to untreated healthy individuals despite adequate power to detect a difference. The results argue against a role for defective leptin secretion or sensitivity in the weight gain induced by antipsychotic medications.

AB - Alterations in plasma leptin have been reported in schizophrenia patients treated with antipsychotics, suggesting the hypothesis that impairments in leptin secretion or signaling might play a role in antipsychotic-induced weight gain. Plasma leptin was measured in 72 schizophrenia patients chronically treated with olanzapine (n = 27), risperldone (n = 24) or typical antipsychotics (n = 21) and 124 healthy adult control subjects, ANCOVA was used to test effects of adiposity (body mass index kg/m2; BMI), subject group (treated patients vs untreated controls), and treatment group (specific medication groups and untreated controls) on plasma leptin concentrations. Additional analyses were performed in a subset of patients and controls individually matched for BMI to further assess group differences in plasma leptin independent of adiposity. BMI strongly predicted plasma leptin concentrations in the overall sample. In addition, a significant three-way interaction between BMI, subject group, and gender was observed. In the individually BMI-matched sample, modestly reduced plasma leptin levels (effect size 0.4 SD) were observed in treated patients in comparison to the BMI-matched healthy controls, with both groups including males and females. However, no differences in plasma leptin levels were observed in the matched sample when separately companng male patients vs untreated male controls and female patients vs untreated female controls. Plasma leptin in chronically treated patients with schizophrenia is strongly predicted by adiposity, similar to untreated healthy individuals despite adequate power to detect a difference. The results argue against a role for defective leptin secretion or sensitivity in the weight gain induced by antipsychotic medications.

KW - Antipsychotics

KW - Human

KW - Leptin

KW - Obesity

KW - Schizophrenia

KW - Weight gain

UR - http://www.scopus.com/inward/record.url?scp=11144259312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144259312&partnerID=8YFLogxK

U2 - 10.1038/sj.npp.1300563

DO - 10.1038/sj.npp.1300563

M3 - Article

C2 - 15367925

AN - SCOPUS:11144259312

VL - 30

SP - 184

EP - 191

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 1

ER -